Discount Mall

Discount Mall Malaria is a barrier of delight people and a risk factor to people in health if we didn't resist rapidly as possible.

Supervision on malaria surveillance system at Mondulkiri, 01-03 December 2020.
01/12/2020

Supervision on malaria surveillance system at Mondulkiri, 01-03 December 2020.

Mosquito 🦟🦟🦟 trapping for cases study at Pu rodet leu village, Bosra commune, Pechreada district, Mondulkiri province.
27/11/2020

Mosquito 🦟🦟🦟 trapping for cases study at Pu rodet leu village, Bosra commune, Pechreada district, Mondulkiri province.

US-CDC:Malaria- The Disease- How People Get Malaria (Transmission)- Who is At Risk- Symptoms and Diagnosis- Preventing M...
15/11/2020

US-CDC:
Malaria

- The Disease
- How People Get Malaria (Transmission)
- Who is At Risk
- Symptoms and Diagnosis
- Preventing Malaria During Travel
- Infants and Children
- Pregnancy, Preconception and Breastfeeding
- Other Preventive Measures
- After Returning from an Area where Malaria Transmission Occurs
- Treating Malaria
- Where Malaria Occurs
- Eradication

What is malaria?
Malaria is a serious and sometimes fatal disease caused by a parasite that commonly infects a certain type of mosquito which feeds on humans. People who get malaria are typically very sick with high fevers, shaking chills, and flu-like illness. Four kinds of malaria parasites infect humans: Plasmodium falciparum, P. vivax, P. ovale, and P. malariae. In addition, P. knowlesi, a type of malaria that naturally infects macaques in Southeast Asia, also infects humans, causing malaria that is transmitted from animal to human (“zoonotic” malaria). P. falciparum is the type of malaria that is most likely to result in severe infections and if not promptly treated, may lead to death. Although malaria can be a deadly disease, illness and death from malaria can usually be prevented.

About 2,000 cases of malaria are diagnosed in the United States each year. The vast majority of cases in the United States are in travelers and immigrants returning from parts of the world where malaria transmission occurs, including sub-Saharan Africa and South Asia.

Globally, the World Health Organization estimates that in 2018, 228 million clinical cases of malaria occurred, and 405,000 people died of malaria, most of them children in Africa. Because malaria causes so much illness and death, the disease is a great drain on many national economies. Since many countries with malaria are already among the poorer nations, the disease maintains a vicious cycle of disease and poverty.

How People Get Malaria (Transmission)
How is malaria transmitted?
Usually, people get malaria by being bitten by an infective female Anopheles mosquito. Only Anopheles mosquitoes can transmit malaria and they must have been infected through a previous blood meal taken from an infected person. When a mosquito bites an infected person, a small amount of blood is taken in which contains microscopic malaria parasites. About 1 week later, when the mosquito takes its next blood meal, these parasites mix with the mosquito’s saliva and are injected into the person being bitten.

Because the malaria parasite is found in red blood cells of an infected person, malaria can also be transmitted through blood transfusion, organ transplant, or the shared use of needles or syringes contaminated with blood. Malaria may also be transmitted from a mother to her unborn infant before or during delivery (“congenital” malaria).

Is malaria a contagious disease?
No. Malaria is not spread from person to person like a cold or the flu, and it cannot be sexually transmitted. You cannot get malaria from casual contact with malaria-infected people, such as sitting next to someone who has malaria.

Who Is at Risk
Who is at risk for malaria?
Anyone can get malaria. Most cases occur in people who live in countries with malaria transmission. People from countries with no malaria can become infected when they travel to countries with malaria or through a blood transfusion (although this is very rare). Also, an infected mother can transmit malaria to her infant before or during delivery.

Who is most at risk of getting very sick and dying from malaria?
Plasmodium falciparum is the type of malaria that most often causes severe and life-threatening malaria; this parasite is very common in many countries in Africa south of the Sahara desert. People who are heavily exposed to the bites of mosquitoes infected with P. falciparum are most at risk of dying from malaria. People who have little or no immunity to malaria, such as young children and pregnant women or travelers coming from areas with no malaria, are more likely to become very sick and die. Poor people living in rural areas who lack access to health care are at greater risk for this disease. As a result of all these factors, an estimated 90% of deaths due to malaria occur in Africa south of the Sahara; most of these deaths occur in children under 5 years of age.

Symptoms and Diagnosis
What are the signs and symptoms of malaria?
Symptoms of malaria include fever and flu-like illness, including shaking chills, headache, muscle aches, and tiredness. Nausea, vomiting, and diarrhea may also occur. Malaria may cause anemia and jaundice (yellow coloring of the skin and eyes) because of the loss of red blood cells. If not promptly treated, the infection can become severe and may cause kidney failure, seizures, mental confusion, coma, and death.

How soon will a person feel sick after being bitten by an infected mosquito?
For most people, symptoms begin 10 days to 4 weeks after infection, although a person may feel ill as early as 7 days or as late as 1 year later. Two kinds of malaria, P. vivax and P. ovale, can occur again (relapsing malaria). In P. vivax and P. ovale infections, some parasites can remain dormant in the liver for several months up to about 4 years after a person is bitten by an infected mosquito. When these parasites come out of hibernation and begin invading red blood cells (“relapse”), the person will become sick.

How do I know if I have malaria for sure?
Most people, at the beginning of the disease, have fever, sweats, chills, headaches, malaise, muscles aches, nausea, and vomiting. Malaria can very rapidly become a severe and life-threatening disease. The surest way for you and your health-care provider to know whether you have malaria is to have a diagnostic test where a drop of your blood is examined under the microscope for the presence of malaria parasites. If you are sick and there is any suspicion of malaria (for example, if you have recently traveled in a country where malaria transmission occurs), the test should be performed without delay.

Preventing Malaria During Travel
I will be traveling outside the United States to an area with malaria. How do I find out what is the best drug to take to prevent malaria?
CDC has a list of all the places in the world where malaria transmission occurs and the malaria drugs that are recommended for prevention in each place.

Many effective antimalarial drugs are available. Your health-care provider and you will decide on the best drug for you, if any, based on your travel plans, medical history, age, drug allergies, pregnancy status, and other factors.

To allow enough time for some of the drugs to become effective and for a pharmacy to prepare any special doses of medicine (especially doses for children and infants), you may need to visit your health-care provider 4-6 weeks before travel. Other malaria medicines only need to be started the day before travel and so last-minute travelers can still benefit from a visit to their health-care provider before traveling.

What is known about the long-term effects of drugs that are commonly used to prevent malaria?
The drugs used to prevent malaria have been shown to be safe and well-tolerated for long term use.

I was born in a country where malaria is present and had malaria as a child, and then moved to the United States many years ago. Do I need to worry about getting malaria when I return home to visit my friends and relatives?
Yes. Anyone who goes to a country where malaria transmission occurs should take precautions against contracting malaria. During the time that you have spent in the United States, you have lost any malaria immunity that you might have had while living in your native country. Without frequent exposure to malaria parasites, your immune system has lost its ability to fight malaria. You are now as much at risk as someone who was born in the United States (a “nonimmune” person). Please consult with your health-care provider or a travel clinic about precautions to take against malaria (preventive drugs and protection against mosquito bites) and against other diseases.

Is it safe to buy my malaria drugs in the country where I will be traveling?
Buying medications abroad has its risks. The drugs could be of poor quality because of the way they are produced. The drugs could contain contaminants or they could be counterfeit drugs and therefore may not provide you the protection you need against malaria. In addition, some medications that are sold overseas are not used anymore in the United States or were never sold here. These drugs may not be safe or their safety has never been evaluated.

It would be best to purchase all the medications that you need before you leave the United States. As a precaution, note the name of the medication(s) and the name of the manufacturer(s). That way, in case of accidental loss, you can replace the drug(s) abroad at a reliable vendor.

Isn’t there a malaria vaccine? And if not, why?
Attempts at producing an effective malaria vaccine and vaccine clinical trials are ongoing. The malaria parasite is a complex organism with a complicated life cycle. The parasite has the ability to evade your immune system by constantly changing its surface, so developing a vaccine against these varying surfaces is very difficult. In addition, scientists do not yet totally understand the complex immune responses that protect humans against malaria. However, many scientists all over the world are working on developing an effective vaccine. Because other methods of fighting malaria, including drugs, insecticides, and insecticide-treated bed nets, have not succeeded in eliminating the disease, the search for a vaccine is considered to be one of the most important research projects in public health.

Malaria and Infants and Children
Should infants and children be given antimalarial drugs?
Yes, but not all types of malaria drugs. Children of any age can get malaria and any child traveling to an area where malaria transmission occurs should use the recommended prevention measures, which often include an antimalarial drug. However, some antimalarial drugs are not suitable for children. Doses are based on the child’s weight.

Pregnancy, Preconception, and Breastfeeding
I live in the United States, am 4 months pregnant, and want to take a 2-week trip to a country where malaria transmission occurs. Is it safe to do so?
CDC advises women who are pregnant or likely to become pregnant not to travel to areas where malaria transmission occurs, if possible. Malaria in pregnant women can be more severe than in women who are not pregnant. Malaria can increase the risk for serious pregnancy problems, including prematurity, miscarriage, and stillbirth. If travel to a malarious area cannot be postponed, use of an effective chemoprophylaxis regimen is essential. However, no preventive drugs are completely effective. Please consider these risks (and other health risks as well) and discuss them with your health-care provider.

I plan to become pregnant after I return from an area where malaria transmission occurs. How long does it take it take for antimalarial drugs to clear the body?
Because there is no evidence that chloroquine and mefloquine are associated with congenital defects when used for preventing malaria (prophylaxis), CDC does not recommend that women planning pregnancy need to wait a specific period of time after their use before becoming pregnant. However, if women or their health-care providers wish to decrease the amount of antimalarial drug in the body before conception, the below table provides information on the half-lives of selected antimalarial drugs. After two, four, and six half-lives, approximately 25%, 6%, and 2% of the drug remain in the body.

Half-lives of selected antimalarial drugs

Drug Half life
Atovaquone 2–3 days
Chloroquine 6–60 days
Doxycycline 12–24 hours
Mefloquine 2–3 weeks
Primaquine 4–7 hours
Proguanil 14–21 hours
Tafenoquine 2 weeks

Is it considered safe for me to breastfeed while taking an antimalarial drug?
There are limited data available about the safety of antimalarial drugs while breastfeeding. However, the amount of antimalarial drug transferred from the nursing mother to her infant is not thought to be harmful to the infant. Very small amounts of the antimalarial drugs chloroquine and mefloquine are excreted in the breast milk of women who are breastfeeding. Although there is limited information about the use of doxycycline in breastfeeding women, most experts consider it unlikely to cause any harm.

No information is available on the amount of primaquine or tafenoquine that enters human breast milk. The mother and infant should be tested for G6PD deficiency before primaquine is given to a woman who is breastfeeding. Because there is no information on the use of tafenoquine in infants, tafenoquine is not recommended during breastfeeding.

It is not known whether atovaquone, which is a component of the antimalarial drug Malarone, is excreted in human milk. Proguanil, the other component of Malarone, is excreted in human milk in small quantities.

Note:

Because there is little information available on the safety of atovaquone/proguanil to prevent malaria in infants weighing less than 5 kg (11 lbs), CDC does not currently recommend it for the prevention of malaria in women breastfeeding infants weighing less than 5 kg.

If I am taking an antimalarial drug and breast-feeding, will my baby be protected from malaria because of the medication transferred in my breast milk?
No. Based on experience with other antimalarial drugs, the quantity of drug transferred in breast milk is not likely to be enough to provide protection against malaria for the infant.

Other Preventive Measures
I am a U.S. citizen and am now living in an area where malaria is a problem. How can I prevent myself and my family from getting sick?
You and your family can most effectively prevent malaria by taking all three of these important measures:

Taking antimalarial medication to kill the parasites and prevent becoming ill
Keeping mosquitoes from biting you, especially at night
Sleeping under insecticide-treated bed nets, using insect repellent, and wearing long-sleeved clothing if out of doors at night.
After Returning from an Area That Has Malaria
How long after returning from an area with malaria could I develop malaria?
Any traveler who becomes ill with a fever or flu-like illness while traveling, and up to 1 year after returning home, should immediately seek professional medical care. You should tell your health-care provider that you have been traveling in an area where malaria transmission occurs and ask to be tested for malaria infection.

Can I give blood if I have been in a country where there is malaria?
It depends on what areas of that country you visited, how long ago you were there, and whether you ever had malaria. In general, most travelers to an area with malaria are deferred from donating blood for 1 year after their return. People who used to live in countries where malaria transmission occurs cannot donate blood for 3 years. People diagnosed with malaria cannot donate blood for 3 years after treatment, during which time they must have remained free of symptoms of malaria.

Blood banks follow strict guidelines for accepting or deferring donors who have been in malaria-endemic areas. They do this to avoid collecting blood for transfusions from an infected donor. In the United States during the period 1963-2012, there were 97 cases reported to CDC where people acquired malaria through a transfusion. Because of these control measures, transfusion-transmitted malaria is very rare in the United States and occurs at a rate of less than 1 per million units of blood transfused.

Treating Malaria
When should malaria be treated?
The disease should be treated early in its course, before it becomes serious and life-threatening. Several good antimalarial drugs are available, and should be taken early on. The most important step is to go see a doctor if you are sick and are presently in, or have recently been in, an area with malaria, so that the disease is diagnosed and treated right away.

What is the treatment for malaria?
Malaria can be cured with prescription drugs. The type of drugs and length of treatment depend on the type of malaria, where the person was infected, their age, whether they are pregnant, and how sick they are at the start of treatment.

For health-care providers treating malaria, please see the CDC Guidelines for Treatment of Malaria in the US.

When is malaria self-treatment recommended?
Very rarely. Travelers who are taking effective malaria preventive drugs but who will be traveling for an extended period of time or who will be at higher risk of developing a malaria infection may decide, in consultation with their health-care provider, to take along malaria treatment medication (referred to as a reliable supply) in case they develop malaria while traveling. If the traveler develops symptoms of malaria, they should immediately seek medical attention so that they can be examined and diagnosed appropriately. If they are diagnosed with malaria, they will then already have with them a reliable supply of an effective malaria treatment medicine to take. Malaria self-treatment should begin right away if fever, chills, or other influenza-like illness symptoms occur and if professional medical care is not available within 24 hours. Self-treatment of a possible malarial infection is only a temporary measure and immediate medical care is important. Appropriate options for a reliable supply of malaria treatment medicines are atovaquone/proguanil or artemether/lumefantrine.

If I get malaria, will I have it for the rest of my life?

No, not necessarily. Malaria can be treated. If the right drugs are used, people who have malaria can be cured and all the malaria parasites can be cleared from their body. However, the disease can continue if it is not treated or if it is treated with the wrong drug. Some drugs are not effective because the parasite is resistant to them. Some people with malaria may be treated with the right drug, but at the wrong dose or for too short a period of time.

Two types (species) of parasites, Plasmodium vivax and P. ovale, have liver stages and can remain in the body for years without causing sickness. If not treated, these liver stages may reactivate and cause malaria attacks (“relapses”) after months or years without symptoms. People diagnosed with P. vivax or P. ovale are often given a second drug to help prevent these relapses. Another type of malaria, P. malariae, if not treated, has been known to stay in the blood of some people for several decades.

However, in general, if you are correctly treated for malaria, the parasites are eliminated and you are no longer infected with malaria.

Where Malaria Occurs
Where does malaria occur?
Malaria typically is found in warmer regions of the world — in tropical and subtropical countries. Higher temperatures allow the Anopheles mosquito to thrive. Malaria parasites, which grow and develop inside the mosquito, need warmth to complete their growth before they are mature enough to be transmitted to humans.

Malaria occurs in more than 100 countries and territories. About half of the world’s population is at risk. Large areas of Africa and South Asia and parts of Central and South America, the Caribbean, Southeast Asia, the Middle East, and Oceania are considered areas where malaria transmission occurs.

Yet malaria does not occur in all warm climates. For example, malaria has been eliminated in some countries with warm climates, while a few other countries have no malaria because Anopheles mosquitoes are not found there.

Why is malaria so common in Africa?
In Africa south of the Sahara, the principal malaria mosquito, Anopheles gambiae, transmits malaria very efficiently. The type of malaria parasite most often found, Plasmodium falciparum, causes severe, potentially fatal disease. Lack of resources and political instability can prevent the building of solid malaria control programs. In addition, malaria parasites are increasingly resistant to antimalarial drugs, presenting one more barrier to malaria control on that continent.

In some countries, malaria is said to exist in “rural” areas. How would one know if an area is rural vs urban?
What constitutes a rural area can vary by country. In general, urbanization can be said to involve both population size and economic development of an area in which there is concentrated commercial activity, such as manufacturing, the sale of goods and services, and transportation. Rural areas tend to have less commercial activity, less population density, more green space, and agriculture may be a main feature.

Eradication and Elimination
Wasn’t malaria eradicated years ago?
No. Eradication means that no more malaria exists in the world. Malaria has been eliminated from many developed countries with temperate climates. However, the disease remains a major health problem in many developing countries, in tropical and subtropical parts of the world.

An eradication campaign was started in the 1950s, but it failed globally because of problems including the resistance of mosquitoes to insecticides used to kill them, the resistance of malaria parasites to drugs used to treat them, and administrative issues. In addition, the eradication campaign never involved most of Africa, where malaria is the most common.

All right reserved by US-CDC, no one correction in any points if not permission from US-CDC.

27/10/2020

WHO: Malaria
14 January 2020

Key facts
Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable.
In 2018, there were an estimated 228 million cases of malaria worldwide.
The estimated number of malaria deaths stood at 405 000 in 2018.
Children aged under 5 years are the most vulnerable group affected by malaria; in 2018, they accounted for 67% (272 000) of all malaria deaths worldwide.
The WHO African Region carries a disproportionately high share of the global malaria burden. In 2018, the region was home to 93% of malaria cases and 94% of malaria deaths.
Total funding for malaria control and elimination reached an estimated US$ 2.7 billion in 2018. Contributions from governments of endemic countries amounted to US$ 900 million, representing 30% of total funding.

Malaria is caused by Plasmodium parasites. The parasites are spread to people through the bites of infected female Anopheles mosquitoes, called "malaria vectors." There are 5 parasite species that cause malaria in humans, and 2 of these species – P. falciparum and P. vivax – pose the greatest threat.

In 2018, P. falciparum accounted for 99.7% of estimated malaria cases in the WHO African Region 50% of cases in the WHO South-East Asia Region, 71% of cases in the Eastern Mediterranean and 65% in the Western Pacific.
P. vivax is the predominant parasite in the WHO Region of the Americas, representing 75% of malaria cases.
Symptoms
Malaria is an acute febrile illness. In a non-immune individual, symptoms usually appear 10–15 days after the infective mosquito bite. The first symptoms – fever, headache, and chills – may be mild and difficult to recognize as malaria. If not treated within 24 hours, P. falciparum malaria can progress to severe illness, often leading to death.

Children with severe malaria frequently develop one or more of the following symptoms: severe anaemia, respiratory distress in relation to metabolic acidosis, or cerebral malaria. In adults, multi-organ failure is also frequent. In malaria endemic areas, people may develop partial immunity, allowing asymptomatic infections to occur.

Who is at risk?
In 2018, nearly half of the world's population was at risk of malaria. Most malaria cases and deaths occur in sub-Saharan Africa. However, the WHO regions of South-East Asia, Eastern Mediterranean, Western Pacific, and the Americas are also at risk.

Some population groups are at considerably higher risk of contracting malaria, and developing severe disease, than others. These include infants, children under 5 years of age, pregnant women and patients with HIV/AIDS, as well as non-immune migrants, mobile populations and travellers. National malaria control programmes need to take special measures to protect these population groups from malaria infection, taking into consideration their specific circumstances.

Disease burden
According to the latest World malaria report, released in December 2019, there were 228 million cases of malaria in 2018 compared to 231 million cases in 2017. The estimated number of malaria deaths stood at 405 000 in 2018, compared with 416 000 deaths in 2017.

The WHO African Region continues to carry a disproportionately high share of the global malaria burden. In 2018, the region was home to 93% of malaria cases and 94% of malaria deaths.

In 2018, 6 countries accounted for more than half of all malaria cases worldwide: Nigeria (25%), the Democratic Republic of the Congo (12%), Uganda (5%), and Côte d’Ivoire, Mozambique and Niger (4% each).

Children under 5 years of age are the most vulnerable group affected by malaria; in 2018, they accounted for 67% (272 000) of all malaria deaths worldwide.
World malaria report 2019

Transmission
In most cases, malaria is transmitted through the bites of female Anopheles mosquitoes. There are more than 400 different species of Anopheles mosquito; around 30 are malaria vectors of major importance. All of the important vector species bite between dusk and dawn. The intensity of transmission depends on factors related to the parasite, the vector, the human host, and the environment.

Anopheles mosquitoes lay their eggs in water, which hatch into larvae, eventually emerging as adult mosquitoes. The female mosquitoes seek a blood meal to nurture their eggs. Each species of Anopheles mosquito has its own preferred aquatic habitat; for example, some prefer small, shallow collections of fresh water, such as puddles and hoof prints, which are abundant during the rainy season in tropical countries.

Transmission is more intense in places where the mosquito lifespan is longer (so that the parasite has time to complete its development inside the mosquito) and where it prefers to bite humans rather than other animals. The long lifespan and strong human-biting habit of the African vector species is the main reason why approximately 90% of the world's malaria cases are in Africa.

Transmission also depends on climatic conditions that may affect the number and survival of mosquitoes, such as rainfall patterns, temperature and humidity. In many places, transmission is seasonal, with the peak during and just after the rainy season. Malaria epidemics can occur when climate and other conditions suddenly favour transmission in areas where people have little or no immunity to malaria. They can also occur when people with low immunity move into areas with intense malaria transmission, for instance to find work, or as refugees.

Human immunity is another important factor, especially among adults in areas of moderate or intense transmission conditions. Partial immunity is developed over years of exposure, and while it never provides complete protection, it does reduce the risk that malaria infection will cause severe disease. For this reason, most malaria deaths in Africa occur in young children, whereas in areas with less transmission and low immunity, all age groups are at risk.

Prevention
Vector control is the main way to prevent and reduce malaria transmission. If coverage of vector control interventions within a specific area is high enough, then a measure of protection will be conferred across the community.

WHO recommends protection for all people at risk of malaria with effective malaria vector control. Two forms of vector control – insecticide-treated mosquito nets and indoor residual spraying – are effective in a wide range of circumstances.

Insecticide-treated mosquito nets
Sleeping under an insecticide-treated net (ITN) can reduce contact between mosquitoes and humans by providing both a physical barrier and an insecticidal effect. Population-wide protection can result from the killing of mosquitoes on a large scale where there is high access and usage of such nets within a community.

In 2018, about half of all people at risk of malaria in Africa were protected by an insecticide-treated net, compared to 29% in 2010. However, ITN coverage has been at a standstill since 2016.

Indoor spraying with residual insecticides
Indoor residual spraying (IRS) with insecticides is another powerful way to rapidly reduce malaria transmission. It involves spraying the inside of housing structures with an insecticide, typically once or twice per year. To confer significant community protection, IRS should be implemented at a high level of coverage.

Globally, IRS protection declined from a peak of 5% in 2010 to 2% in 2018, with decreases seen across all WHO regions, apart from the WHO Eastern Mediterranean Region. The declines in IRS coverage are occurring as countries switch from pyrethroid insecticides to more expensive alternatives to mitigate mosquito resistance to pyrethroids.

Antimalarial drugs
Antimalarial medicines can also be used to prevent malaria. For travellers, malaria can be prevented through chemoprophylaxis, which suppresses the blood stage of malaria infections, thereby preventing malaria disease. For pregnant women living in moderate-to-high transmission areas, WHO recommends intermittent preventive treatment with sulfadoxine-pyrimethamine, at each scheduled antenatal visit after the first trimester. Similarly, for infants living in high-transmission areas of Africa, 3 doses of intermittent preventive treatment with sulfadoxine-pyrimethamine are recommended, delivered alongside routine vaccinations.

Since 2012, WHO has recommended seasonal malaria chemoprevention as an additional malaria prevention strategy for areas of the Sahel sub-region of Africa. The strategy involves the administration of monthly courses of amodiaquine plus sulfadoxine-pyrimethamine to all children under 5 years of age during the high transmission season.

Insecticide resistance
Since 2000, progress in malaria control has resulted primarily from expanded access to vector control interventions, particularly in sub-Saharan Africa. However, these gains are threatened by emerging resistance to insecticides among Anopheles mosquitoes. According to the latest World malaria report, 73 countries reported mosquito resistance to at least 1 of the 4 commonly-used insecticide classes in the period 2010-2018. In 27 countries, mosquito resistance was reported to all of the main insecticide classes.

Despite the emergence and spread of mosquito resistance to pyrethroids, insecticide-treated nets continue to provide a substantial level of protection in most settings. This was evidenced in a large 5-country study coordinated by WHO between 2011 and 2016.

While the findings of this study are encouraging, WHO continues to highlight the urgent need for new and improved tools in the global response to malaria. To prevent an erosion of the impact of core vector control tools, WHO also underscores the critical need for all countries with ongoing malaria transmission to develop and apply effective insecticide resistance management strategies.

Diagnosis and treatment
Early diagnosis and treatment of malaria reduces disease and prevents deaths. It also contributes to reducing malaria transmission. The best available treatment, particularly for P. falciparum malaria, is artemisinin-based combination therapy (ACT).

WHO recommends that all cases of suspected malaria be confirmed using parasite-based diagnostic testing (either microscopy or rapid diagnostic test) before administering treatment. Results of parasitological confirmation can be available in 30 minutes or less. Treatment, solely on the basis of symptoms should only be considered when a parasitological diagnosis is not possible. More detailed recommendations are available in the third edition of the "WHO Guidelines for the treatment of malaria", published in April 2015.

Antimalarial drug resistance
Resistance to antimalarial medicines is a recurring problem. Resistance of P. falciparum malaria parasites to previous generations of medicines, such as chloroquine and sulfadoxine-pyrimethamine (SP), became widespread in the 1950s and 1960s, undermining malaria control efforts and reversing gains in child survival.

Protecting the efficacy of antimalarial medicines is critical to malaria control and elimination. Regular monitoring of drug efficacy is needed to inform treatment policies in malaria-endemic countries, and to ensure early detection of, and response to, drug resistance.

In 2013, WHO launched the Emergency response to artemisinin resistance (ERAR) in the Greater Mekong subregion (GMS), a high-level plan of attack to contain the spread of drug-resistant parasites and to provide life-saving tools for all populations at risk of malaria. But even as this work was under way, additional pockets of resistance emerged independently in new geographic areas of the subregion. In parallel, there were reports of increased resistance to ACT partner drugs in some settings. A new approach was needed to keep pace with the changing malaria landscape.

At the World Health Assembly in May 2015, WHO launched the Strategy for malaria elimination in the Greater Mekong subregion (2015–2030), which was endorsed by all the countries in the subregion. Urging immediate action, the strategy calls for the elimination of all species of human malaria across the region by 2030, with priority action targeted to areas where multidrug resistant malaria has taken root.

With technical guidance from WHO, all countries in the region have developed national malaria elimination plans. Together with partners, WHO is providing ongoing support for country elimination efforts through the Mekong Malaria Elimination programme, an initiative that evolved from the ERAR
Surveillance
Surveillance entails tracking of the disease and programmatic responses, and taking action based on the data received. Currently, many countries with a high burden of malaria have weak surveillance systems and are not in a position to assess disease distribution and trends, making it difficult to optimize responses and respond to outbreaks.

Effective surveillance is required at all points on the path to malaria elimination. Stronger malaria surveillance systems are urgently needed to enable a timely and effective malaria response in endemic regions, to prevent outbreaks and resurgences, to track progress, and to hold governments and the global malaria community accountable.

In March 2018, WHO released a reference manual on malaria surveillance, monitoring and evaluation. The manual provides information on global surveillance standards and guides countries in their efforts to strengthen surveillance systems.

Elimination
Malaria elimination is defined as the interruption of local transmission of a specified malaria parasite species in a defined geographical area as a result of deliberate activities. Continued measures are required to prevent re-establishment of transmission. Malaria eradication is defined as the permanent reduction to zero of the worldwide incidence of malaria infection caused by human malaria parasites as a result of deliberate activities. Interventions are no longer required once eradication has been achieved.

Globally, the elimination net is widening, with more countries moving towards the goal of zero malaria. In 2018, 27 countries reported fewer than 100 indigenous cases of the disease, up from 17 countries in 2010.

Countries that have achieved at least 3 consecutive years of 0 indigenous cases of malaria are eligible to apply for the WHO certification of malaria elimination. Over the last decade, 10 countries have been certified by the WHO Director-General as malaria-free: Morocco (2010), Turkmenistan (2010), Armenia (2011), Maldives (2015), Sri Lanka (2016), Kyrgyzstan (2016), Paraguay (2018), Uzbekistan (2018), Algeria (2019) and Argentina (2018). The WHO Framework for Malaria Elimination (2017) provides a detailed set of tools and strategies for achieving and maintaining elimination.

Vaccines against malaria
RTS,S/AS01 (RTS,S) is the first and, to date, the only vaccine to show that it can significantly reduce malaria, and life-threatening severe malaria, in young African children. It acts against P. falciparum, the most deadly malaria parasite globally and the most prevalent in Africa. Among children who received 4 doses in large-scale clinical trials, the vaccine prevented approximately 4 in 10 cases of malaria over a 4-year period.

In view of its public health potential, WHO’s top advisory bodies for malaria and immunization have jointly recommended phased introduction of the vaccine in selected areas of sub-Saharan Africa. Three countries – Ghana, Kenya and Malawi – began introducing the vaccine in selected areas of moderate and high malaria transmission in 2019. Vaccinations are being provided through each country’s routine immunization programme.

The pilot programme will address several outstanding questions related to the public health use of the vaccine. It will be critical for understanding how best to deliver the recommended 4 doses of RTS,S; the vaccine’s potential role in reducing childhood deaths; and its safety in the context of routine use.

This WHO-coordinated programme is a collaborative effort with Ministries of Health in Ghana, Kenya and Malawi and a range of in-country and international partners, including PATH, a non-profit organization, and GSK, the vaccine developer and manufacturer.

Financing for the vaccine programme has been mobilized through a collaboration between 3 major global health funding bodies: Gavi, the Vaccine Alliance, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and Unitaid.
WHO response
WHO Global technical strategy for malaria 2016-2030
The WHO Global technical strategy for malaria 2016-2030 – adopted by the World Health Assembly in May 2015 – provides a technical framework for all malaria-endemic countries. It is intended to guide and support regional and country programmes as they work towards malaria control and elimination.

The Strategy sets ambitious but achievable global targets, including:

reducing malaria case incidence by at least 90% by 2030;
reducing malaria mortality rates by at least 90% by 2030;
eliminating malaria in at least 35 countries by 2030;
preventing a resurgence of malaria in all countries that are malaria-free.
This Strategy was the result of an extensive consultative process that spanned 2 years and involved the participation of more than 400 technical experts from 70 Member States.

The Global Malaria Programme
The WHO Global Malaria Programme coordinates WHO's global efforts to control and eliminate malaria by:

setting, communicating and promoting the adoption of evidence-based norms, standards, policies, technical strategies, and guidelines;
keeping independent score of global progress;
developing approaches for capacity building, systems strengthening, and surveillance; and
identifying threats to malaria control and elimination as well as new areas for action.
The Programme is supported and advised by the Malaria Policy Advisory Committee (MPAC), a group of global malaria experts appointed following an open nomination process. The mandate of MPAC is to provide strategic advice and technical input, and extends to all aspects of malaria control and elimination, as part of a transparent, responsive and credible policy-setting process.

"High burden high impact approach"
At the World Health Assembly in May 2018, the WHO Director-General, Dr Tedros Adhanom Ghebreyesus, called for an aggressive new approach to jump-start progress against malaria. A new country-driven response – “ High burden to high impact” – was launched in Mozambique in November 2018.

The approach is currently being driven by the 11 countries that carry a high burden of the disease (Burkina Faso, Cameroon, Democratic Republic of the Congo, Ghana, India, Mali, Mozambique, Niger, Nigeria, Uganda and United Republic of Tanzania). Key elements include:

political will to reduce the toll of malaria;
strategic information to drive impact;
better guidance, policies and strategies; and
a coordinated national malaria response.
Catalysed by WHO and the RBM Partnership to End Malaria, “High burden to high impact” builds on the principle that no one should die from a disease that can be prevented and diagnosed, and that is entirely curable with available treatments.

Address

National Center For Parasitology, Entomology And Malaria Control
Phnom Penh

Telephone

+85512310725

Website

Alerts

Be the first to know and let us send you an email when Discount Mall posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Discount Mall:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category